Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | UCT-01-097 |
| Synonyms | |
| Therapy Description |
UCT-01-097 inhibits Erk1 and Erk2, which potentially decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 4044). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| UCT-01-097 | UCT 01-097|UCT01-097 | ERK Inhibitor (pan) 21 | UCT-01-097 inhibits Erk1 and Erk2, which potentially decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 4044). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04761601 | Phase I | Gemcitabine + Paclitaxel + UCT-01-097 UCT-01-097 | First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors | Terminated | USA | 0 |